Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (Ozempic, Rybelsus) and chronic weight management (Wegovy) in adults, with Wegovy also approved for adolescents 12 years and older with obesity
Description Semhil 3 mg is an oral formulation of semaglutide , a GLP-1 receptor agonist used to improve blood sugar control in adults with Type 2 Diabetes Mellitus
A recent decision from the Federal Circuit has seriously called into question whether it was proper for Novo Nordisk to list these patents in the Orange Book (discussed below in connection with Wegovy and Rybelsus.) Either way, the injection device patents most likely did not impact the negotiated entry date for the generics since they will all expire before the 343 and 462 patents
Some insurance plans may also require prior authorization before approving coverage for tirzepatide
There were no differences between the groups in trabecular MAR ([95% CI 0.3 to 0.6]: p = 0.836), cortical MAR ([95% CI 0.7 to 0.5]: p = 0.382), trabecular MS/BS ([95% CI 1.7 to 6.2]: p = 0.318), cortical MS/BS ([95% CI 8.4 to 4.6]: p = 0.791), trabecular BFR ([95% CI 2.1 to 4.6]: p = 0.480), or cortical BFR ([95% CI 13.7 to 3.2]: p = 0.836) (Table 2)
